Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis
Open Access
- 6 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (10), 2393-2401
- https://doi.org/10.1038/s41423-020-0439-2
Abstract
A long duration of treatment and emerging drug resistance pose significant challenges for global tuberculosis (TB) eradication efforts. Therefore, there is an urgent need to develop novel strategies to shorten TB treatment regimens and to treat drug-resistant TB. Using an albumin-fusion strategy, we created a novel albumin-fused granulocyte-macrophage colony-stimulating factor (albGM-CSF) molecule that harnesses albumin's long half-life and targeting abilities to enhance the biostability of GM-CSF and direct it to the lymph nodes, where the effects of GM-CSF can increase dendritic cell populations crucial for eliciting a potent immune response. In this study, we demonstrate that albGM-CSF serves as a novel immunotherapy for chronic Mycobacterium tuberculosis (Mtb) infections by enhancing GM-CSF biostability in serum. Specifically, albumin is very safe, stable, and has a long half-life, thereby enhancing the biostability of GM-CSF. In the lungs and draining lymph nodes, albGM-CSF is able to increase the numbers of dendritic cells, which are crucial for the activation of naive T cells and for eliciting potent immune responses. Subcutaneous administration of albGM-CSF alone reduced the mean lung bacillary burden in mice with chronic tuberculosis infection. While GM-CSF administration was associated with IL-1 beta release from Mtb-infected dendritic cells and macrophages, higher IL-1 beta levels were observed in albGM-CSF-treated mice with chronic tuberculosis infection than in mice receiving GM-CSF. Albumin fusion with GM-CSF represents a promising strategy for the control of chronic lung tuberculosis infections and serves as a novel therapeutic vaccination platform for other infectious diseases and malignancies.Funding Information
- Foundation for the National Institutes of Health (R21AI22922)
This publication has 79 references indexed in Scilit:
- The Polyphosphate Kinase Gene ppk2 Is Required for Mycobacterium tuberculosis Inorganic Polyphosphate Regulation and VirulencemBio, 2013
- Immunotherapeutic effects of recombinant adenovirus encoding granulocyte–macrophage colony-stimulating factor in experimental pulmonary tuberculosisClinical and Experimental Immunology, 2013
- Rifapentine Is Not More Active than Rifampin against Chronic Tuberculosis in Guinea PigsAntimicrobial Agents and Chemotherapy, 2012
- GM-CSF Signalling Boosts Dramatically IL-1ProductionPLOS ONE, 2011
- Efficient mucosal vaccination mediated by the neonatal Fc receptorNature Biotechnology, 2011
- Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin BindingOnline Journal of Public Health Informatics, 2010
- Mycobacterium tuberculosis-specific CD4+, IFNγ+, and TNFα+ multifunctional memory T cells coexpress GM-CSFCytokine, 2008
- Characterisation of the expression and function of the GM‐CSF receptor α‐chain in miceEuropean Journal of Immunology, 2007
- Albumin Binding to FcRn: Distinct from the FcRn−IgG InteractionBiochemistry, 2006
- Mouse and human dendritic cell subtypesNature Reviews Immunology, 2002